The New York Times
~11 min read · 2021-05-09 · Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Reader View ·
Shared by 210, including Shelley Bonanno, MA, LLP (she/her/hers), Chris Brogan/Chief of Staff, Daniel Kraft, MD, Sai Kan, Marvin “Polymath but really Just Generalist” Liao, MAPS, Vaughan Bell, Bjorn Larsen, Rick Powell, Forbes India, Dorlee Michaeli, MBA, LCSW, Scott Galloway, Brian D. Earp, Ph.D.